Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ambu strengthens European presence with Medicotest

This article was originally published in Clinica

Executive Summary

Ambu, which manufactures hospital equipment, is to pay DKr190 million ($24 million) in cash and shares to buy fellow Danish company Medicotest, Europe's leading supplier of disposable electrodes for ECG, neurology and defibrillation applications. Medicotest founder Jan Rasmussen, who holds the absolute majority of shares in the company, will receive DKr117 million in cash. Mr Rasmussen is expected to take a seat on the board.

You may also be interested in...



New EU Approvals

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add a new product – Tibsovo, Servier’s treatment for IDH1-mutated acute myeloid leukemia and IDH1-mutated cholangiocarcinoma.

AstraZeneca’s IBD Hopes Deflated Amid Evolving Market And Pipeline Competition

The major’s attempt to break into Crohn’s disease and ulcerative colitis has been cut short as a highly competitive market and pipeline, intensified by the entrance of biosimilars, renders further development of brazikumab impractical.

Europe's Unitary Patent System Starts Up Today

The forthcoming unitary patent system and Unified Patent Court promise to make applying for patents in Europe and litigating infringements simpler and less costly for applicants.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT070509

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel